DOCSLIB.ORG

Reference List Concerning Spinal Adhesive Arachnoiditis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SPINAL ADHESIVE ARACHNOIDITIS RMA ID Reference List for RMA363-2 as at June 2020 Number Abel TJ, Howard MA 3rd, Menezes A (2014). Syringomyelia and spinal arachnoiditis resulting from aneurysmal subarachnoid hemorrhage: 94310 Report of two cases and review of the literature. J Craniovertebr Junction Spine, 5(1): 47-51. Abhinav K, Bradley M, Aquilina K, et al (2012). Spinal arachnoiditis and 72882 cyst formation with subarachnoid haemorrhage. Br J Neurosurg, 26(4): 574-5. Abouleish E, Vega S, Blendinger I, et al (1975). Long-term follow-up of 94392 epidural blood patch. Anesth Analg, 54(4): 459-63. Agrawal A, Agrawal A, Agrawal C, et al (2006). An unusual spinal 59948 arachnoiditis. Clin Neurol Neurosurg, 108(8): 775-9. Al Maach N, Vogels OJ, Bollen TL, et al (2010). Arachnoiditis and 59949 communicating hydrocephalus as a complication of epidural blood patch. J Neurol, 257(4): 672-3. Aldrete JA (2003). Neurologic deficits and arachnoiditis following 59950 neuroaxial anesthesia. Acta Anaesthesiol Scand, 47(1): 3-12. Aldrete JA (2004). [Comment] Chronic adhesive arachnoiditis. Br J 59947 Anaesth, 93(2): 301; Author reply 301-3. Aldrete JA, Brown TL (1997). [Comment] Intrathecal hematoma and 94322 arachnoiditis after prophylactic blood patch through a catheter. Anesth Analg, 84(1): 233-4. Anderson TL, Morris JM, Wald JT, et al (2017). Imaging appearance of 94311 advanced chronic adhesive arachnoiditis: a retrospective review. AJR Am J Roentgenol, 209(3): 648-55. Anim-Somuah M, Smyth R, Howell C (2005). Epidural versus non- 60550 epidural or no analgesia in labour. Cochrane Database Syst Rev, 4: CD000331. Aoyama T, Hida K (2010). Spinal intradural granuloma as a complication 61450 of an infected cerebrospinal fluid drainage tube fragment--case report. Neurol Med Chir (Tokyo), 50(2): 165-7. Arai A, Aihara H, Miyake S, et al (2011). Syringomyelia due to thoracic 61449 spinal stenosis with ossified ligamentum flavum--case report. Neurol Med Chir (Tokyo), 51(2): 157-9. Arcos-Algaba A, Serramito-Garcia R, Santin-Amo JM, et al (2009). 94312 [Lumbosacral arachnoiditis secondary to a lumboperitoneal shunt]. Rev Neurol, 49(10): 547-8 [Article in Spanish]. [Abstract] Arslanoglu A, Aygun N (2007). Magnetic resonance imaging of cauda 94376 equina syndrome in long-standing ankylosing spondylitis. Australas Radiol, 51(4): 375-7. Australian Arachnoiditis Sufferers Association NSW (2005). Adhesive 61470 arachnoiditis MRI diagnosis. Retrieved 7 June 2011, from http://www.aasansw.org.au/president'spage.htm Page 1 of 13 Bakhsh WR, Mesfin A, Bridwell KH (2013). Arachnoiditis ossificans after 94313 revision adolescent idiopathic scoliosis surgery: a 22-year follow-up and review. Spine (Phila Pa 1976), 38(18): E1166-70. Barolat G (1993). Experience with 509 plate electrodes implanted 94333 epidurally from C1 to L1. Stereotact Funct Neurosurg, 61(2): 60-79. [Abstract] Barros GA, Marques ME, Ganem EM (2007). The effects of intrathecal 94403 administration of betamethasone over the dogs' spinal cord and meninges. Acta Cir Bras, 22(5): 361-5. Basaran R, Kaksi M, Efendioglu M, et al (2015). Spinal arachnoid cyst associated with arachnoiditis following subarachnoid haemorrhage in 94314 adult patients: a case report and literature review. Br J Neurosurg, 29(2): 285-9. Bay A, Oner AF, Etlik O, et al (2005). Myelopathy due to intrathecal 94336 chemotherapy: report of six cases. J Pediatr Hematol Oncol, 27(5): 270- 2. Bejjani GK, Karim NO, Tzortzidis F (1997). Intrathecal granuloma after 94334 implantation of a morphine pump: case report and review of the literature. Surg Neurol, 48(3): 288-91. Bell RB, Wallace CJ, Swanson HA, et al (1995). Ossification of the 60562 lumbosacral dura and arachnoid following spinal cord trauma. Case report. Paraplegia, 33(9): 543-6. Bendersky D, Yampolsky C (2014). Is spinal cord stimulation safe? A 94335 review of its complications. World Neurosurg, 82(6): 1359-68. Bernard P, Vanhoenacker FM, Adam N (2010). Arachnoiditis ossificans. 60128 JBR-BTR, 93(2): 108. Bilgen IG, Yunten N, Ustun EE, et al (1999). Adhesive arachnoiditis causing cauda equina syndrome in ankylosing spondylitis: CT and MRI 94337 demonstration of dural calcification and a dorsal dural diverticulum. Neuroradiology, 41(7): 508-11. Bilston LE, Fletcher DF, Stoodley MA (2006). Focal spinal arachnoiditis 59951 increases subarachnoid space pressure: a computational study. Clin Biomech (Bristol, Avon), 21(6): 579-84. Bogod D (2012). The sting in the tail: antiseptics and the neuraxis 95663 revisited. Anaesthesia, 67(12): 1305-9. Boonmak P, Boonmak S (2010). Epidural blood patching for preventing 60551 and treating post-dural puncture headache. Cochrane Database Syst Rev, 1: CD001791. Boyd JT, Langlands AO, Maccabe JJ (1968). Long-term hazards of 94497 Thorotrast. Br Med J, 2(5604): 517-21. Brain E, Alexandre J, Minozzi C, et al (1997). [High-dose methotrexate 94338 and cerebral neurotoxicity. Apropos of a case of arachnoiditis]. Presse Med, 26(6): 265-8 [Article in French]. [Abstract] Brodbelt AR, Stoodley MA (2003). Post-traumatic syringomyelia: a 61263 review. J Clin Neurosci, 10(4): 401-8. Brodsky AE (1978). Cauda equina arachnoiditis. A correlative clinical and 94498 roentgenologic study. Spine (Phila Pa 1976), 3(1): 51-60. Burgett RA, Purvin VA, Kawasaki A (1997). Lumboperitoneal shunting for 94499 pseudotumor cerebri. Neurology, 49(3): 734-9. Butterworth JF, Lahaye L (2019). Clinical use of local anesthetics in anesthesia. Retrieved 14 February 2020, from 94339 https://www.uptodate.com/contents/clinical-use-of-local-anesthetics-in- anesthesia Canova G, Boaro A, Giordan E, et al (2017). Treatment of posttubercular 94340 syringomyelia not responsive to antitubercular therapy: case report and review of literature. J Neurol Surg Rep, 78(2): e59-67. Page 2 of 13 Carlsward C, Darvish B, Tunelli J, et al (2015). Chronic adhesive 94341 arachnoiditis after repeat epidural blood patch. Int J Obstet Anesth, 24(3): 280-3. Carmouche JJ, Molinari RW (2004). Epidural abscess and discitis 60565 complicating instrumented posterior lumbar interbody fusion: a case report. Spine (Phila Pa 1976), 29(23): E542-6. Chan CC, Lau PY, Sun LK, et al (2009). Arachnoiditis ossificans. Hong 61475 Kong Med J, 15(2): 146-8. Chan YC, Dasey N (2007). Iatrogenic spinal epidural abscess. Acta Chir 60561 Belg, 107(2): 109-18. Chang HS, Nakagawa H (2004). Theoretical analysis of the 61452 pathophysiology of syringomyelia associated with adhesive arachnoiditis. J Neurol Neurosurg Psychiatry, 75(5): 754-7. Charlesworth CH, Savy LE, Stevens J, et al (1996). MRI demonstration 94347 of arachnoiditis in cauda equina syndrome of ankylosing spondylitis. Neuroradiology, 38(5): 462-5. Chattopadhyay I, Jha AK, Banerjee SS, et al (2016). Post-procedure 94348 adhesive arachnoiditis following obstetric spinal anaesthesia. Indian J Anaesth, 60(5): 372-4. Cohn J, Moaveni D, Sznol J, et al (2016). Complications of 761 short- 94349 term intrathecal macrocatheters in obstetric patients: a retrospective review of cases over a 12-year period. Int J Obstet Anesth, 25: 30-6. Collighan N, Gupta S (2010). Epidural steroids. Continuing Education in 61473 Anaesthesia Critical Care & Pain, 10(1): 1-5. Cooper SD, Brady MB, Williams JP, et al (1988). Neurosarcoidosis: 94350 evaluation using computed tomography and magnetic resonance imaging. J Comput Tomogr, 12(2): 96-9. Cornelson SM, Johnnie ED, Kettner NW (2018). Neural mobilization in a 94351 54-year-old woman with postoperative spinal adhesive arachnoiditis. J Chiropr Med, 17(4): 283-8. Cosan TE, Kabukcuoglu S, Arslantas A, et al (2001). Spinal toxoplasmic 59952 arachnoiditis associated with osteoid formation: a rare presentation of toxoplasmosis. Spine (Phila Pa 1976), 26(15): 1726-8. Couto de Silva JM, Couto de Silva JM Jr, Antonio Aldrete J (2001). Body 61453 temperature and diaphoresis disturbances in a patient with arachnoiditis. Anesth Analg, 93(6): 1578-9. Crespo Martinez C, Castro Copete MC (2018). Adhesive arachnoiditis 95664 secondary to the use of intrathecal liposoluble contrast. Radiologia, 60(3): 267-9. Crete RN, Gallmann W, Karis JP, et al (2018). Spinal 94352 coccidioidomycosis: MR imaging findings in 41 patients. AJNR Am J Neuroradiol, 39(11): 2148-53. Cunha I, Nour D, Silva JA, et al (2006). [Ossifying arachnoiditis in 94353 spondyloarthropathy patient]. Acta Reumatol Port, 31(3): 263-71 [Article in Portuguese]. [Abstract] da Silva RA, Ferraz IL, Zuza RS, et al (2019). Can an inflammatory reaction in the meninges, caused by spinal puncture through tattooed 94354 skin, evolve into adhesive arachnoiditis? An experimental model in rabbits. Reg Anesth Pain Med, 44: 355-9. Davies MJ (2007). Perioperative epidural anaesthesia and analgesia--an 60664 appraisal of its role. Anaesth Intensive Care, 35(4): 593-600. De Andres J, Palmisani S, Villanueva Perez VL, et al (2010). Can an 94355 intrathecal, catheter-tip-associated inflammatory mass reoccur? Clin J Pain, 26(7): 631-4. Page 3 of 13 Deer TR, Prager J, Levy R, et al (2012). Polyanalgesic Consensus Conference--2012: consensus on diagnosis, detection, and treatment of 94356 catheter-tip granulomas (inflammatory masses). Neuromodulation, 15(5): 483-96. DeSanto J, Ross JS (2011). Spine infection/inflammation. Radiol Clin 60560 North Am, 49(1): 105-27. Deyo RA, Mirza SK, Turner JA, et al (2009). Overtreating chronic back 61457 pain: time to back off? J Am Board Fam Med, 22(1): 62-8. Diaz JH (2002). Permanent paraparesis and cauda equina syndrome 94357 after epidural blood patch for postdural puncture headache. Anesthesiology, 96(6): 1515-7. Domenicucci M, Ramieri A, Passacantilli E, et al (2004). Spinal 59953 arachnoiditis ossificans: report of three cases. Neurosurgery, 55(4): 985. Dong A, Zuo C, Zhang P, et al (2014). MRI and FDG PET/CT findings in 94358 3 cases of spinal infectious arachnoiditis. Clin Nucl Med, 39(10): 900-3. Dossani RH, Patra DP, Sun H, et al (2018). Delayed spinal arachnoiditis 94359 following aneurysmal subarachnoid hemorrhage: a case report. Cureus, 10(1): e2031. Douglas MJ, Swenerton JE (2002).
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini

    Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini

    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
  • Pharmaceuticals Appendix

    Pharmaceuticals Appendix

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • I (Acts Whose Publication Is Obligatory) COMMISSION

    I (Acts Whose Publication Is Obligatory) COMMISSION

    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini

    Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini

    Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini CONTRAST AGENTS - FULL LIST OF THE 30 IODINATED PRODUCTS FOR WHICH REPORTS HAVE BEEN SENT OVER THE FIRST 40 YEARS OF THE WHO PHARMACOVIGILANCE SYSTEM, SUBDIVIDED INTO TWO 20-YEAR PERIODS. FOURTH WHO-ITA/ITA-OMS 2010-2011 CONTRIBUTION ON THE 30 BASIC AGGREGATED WHO SYSTEM-ORGAN CLASS DISORDERS (SOCDs), AND SUSPECTED+ ADVERSE REACTIONS AND EVENT PREFERRED NAMES (SADRs+) Dan Bradu and Luigi Rossini* Servizio Nazionale collaborativo WHO-ITA/ITA-OMS, Universita’ Politecnica delle Marche e Progetto di Farmacotossicovigilanza pre-, post-marketing, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary We have examined the PR-22 2010 data set, which includes 155,164 accepted SADRs associated with 30 iodinated contrast agents in use in the Countries participating in the WHO Pharmacovigilance Programme. The SADRs encompass 40 years, from 1968 to 2010, divided into two 20 year periods (1968-1989 and 1990-2010). The data, provided by the UMC, have been analysed in the framework of the Matlab software of correlation clustering leading to an objective classification based on the 30 standard WHO-SOCDs and preferred names. As reflected in the Title the first set of analyses regarded ATC-V08A sub-classes A (9 agents; 63,578 reports), B (12; 84,105), and C (8; 7,171). These were examined 701 Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini separately, then the results of the same procedure applied to the full matrix of 30 products and ―876 non empty‖ SADRs, including ATC-V08A sub-class D (1 agent; 310 reports) were displayed in the Appendices.
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
  • Marrakesh Agreement Establishing the World Trade Organization

    Marrakesh Agreement Establishing the World Trade Organization

    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX